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Abstract
Background: Coronary bifurcation treatment poses a therapeutic challenge. The aim of this study was 
to analyze pooled data of two randomized clinical trials, POLBOS I and POLBOS II, to compare 1-year 
follow-up results and identify possible prognostic factors.
Methods: In POLBOS trials dedicated bifurcation BiOSS® stents were compared with regular drug 
eluting stents (rDES) in patients with stable coronary artery disease or non ST-segment elevation acute 
coronary syndrome (POLBOS I: paclitaxel eluting BiOSS® Expert vs. rDES; POLBOS II: sirolimus 
eluting BiOSS® LIM vs. rDES). Provisional T-stenting was the default strategy. Angiographic control 
was performed at 12 months. The primary endpoint was major adverse cardiovascular events (MACE) 
rate defined as the rate of cardiac death, myocardial infarction (MI) or target lesion revascularization 
(TLR). 
Results: 445 patients, with 222 patients in the BiOSS group and 223 patients in the rDES group, 
were analyzed. In 26.7% cases procedures were performed within distal left main, and true bifurca-
tions which accounted for 81.6% of treated lesions. At 12 months the whole population exhibited no 
statistical differences in terms of MACE, TLR, MI or cardiac death between rDES and BiOSS groups. 
In multivariate analysis odds for MACE decreased with female sex (OR 0.433, 95% CI 0.178–0.942,  
p = 0.047) and with proximal optimization technique use (OR 0.208, 95% CI 0.097–0.419, p < 0.001), 
whereas the odds for MACE increased with main vessel predilatation (OR 2.191, 95% CI 1.042–5.066, 
p = 0.049) and diabetes mellitus treated with insulin (OR 2.779, 95% CI 1.1–6.593, p = 0.024). 
Conclusions: Pooled data showed no significant difference between MACE and TLR rates for BiOSS® 
group vs. rDES group. (Cardiol J 2018; 25, 3: 308–316)
Key words: coronary bifurcation, drug eluting stent, proximal optimization technique, 
left main, diabetes mellitus
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Introduction
The activity of European Bifurcation Club, 
initiated in 2004, has led to issuing practical recom-
mendations to improve outcomes after percutane-
ous treatment of coronary bifurcation lesions [1]. 
Recent reports have suggested that clinical out-
comes after percutaneous coronary interventions 
(PCI) of bifurcation lesions were no longer worse 
than after PCI of non-bifurcation lesions or that 
differences were only minimal and limited to the 
early phase postprocedural events [2, 3]. However, 
variety of bifurcations’ anatomy induced search-
ing for stents designed for coronary bifurcation 
by definition. Until that moment, big expectations 
associated with them have not been realized [4]. 
The BiOSS® dedicated coronary bifurcation stent 
has been extensively tested in many clinical sce-
narios, however, and especially important is that 
there are two randomized studies, POLBOS I and 
POLBOS II, comparing dedicated bifurcation with 
regular drug-eluting stents (rDES). Indeed, pooled 
data from those two studies allowed performing 
a detailed comparative analysis. 
The aim of this study was to analyze pooled 
data of two clinical trials POLBOS I and POLBOS II 
in order to compare 1-year follow-up results and 
identify possible prognostic factors in the overall 
population as well as in diabetic and left main (LM) 
subgroups [5, 6].
Methods
Study population and study design
The POLBOS I and POLBOS II were inter-
national, multi-center, randomized, open-label, 
controlled trials, which are described elsewhere 
[5, 6]. Briefly, the inclusion criteria were: stable 
coronary artery disease or non ST-segment el-
evation acute coronary syndrome, age ≥ 18 years, 
de novo coronary bifurcation lesion (including un-
protected LM stem), main vessel (MV) diameter 
≥ 2.5 mm and side branch (SB) diameter ≥ 2.0 mm, 
based on visual estimation. Main exclusion criteria 
were: ST-segment elevation myocardial infarction, 
Medina 0,0,1 bifurcations, baseline serum creati-
nine level ≥ 177 µmol/L (2.0 mg/dL), inability to un-
dergo dual antiplatelet therapy for 12 months, left 
ventricular ejection fraction ≤ 30%, and the lack of 
informed consent. The Institutional Review Board 
of each participating center approved the study 
protocol (ClinicalTrials.gov Identifier: POLBOS I 
— NCT02192840, POLBOS II — NCT02198300). 
Interventional procedure, device description 
and concomitant medication
After signing informed consent patients were 
randomly assigned to one of two treatment strate-
gies: BiOSS Expert® (in POLBOS I)/BiOSS LIM® 
(in POLBOS II) stent implantation or rDES im-
plantation. Patients randomized to the rDES group 
underwent a second randomization: completing 
the procedure with or without final kissing balloon 
technique (FKB). Provisional T-stenting was the 
default strategy in both treatment groups. A single 
stent was implanted in the MV-MB across the side 
branch in all patients.
The BiOSS® is a coronary, dedicated balloon-
expandable bifurcation stent. The platform is made 
of 316L stainless steel (strut thickness 120 µm) and 
the stent is coated with a biodegradable polymer that 
elutes paclitaxel (BiOSS® Expert — paclitaxel con-
centration 1 µg/mm2) or sirolimus (BIOSS® LIM — 
sirolimus concentration — 1.4 µg/mm2). The BiOSS® 
stent consists of two parts, proximal and distal, joined 
with two connection struts in the middle zone [7]. In 
the rDES group, use of any approved rDES available 
in participating cath labs was allowed. POLBOS I 
trial started in 2010 when paclitaxel-eluting stents 
(PES) were routinely used. The following regular 
PES were used: LucChopin2 (1 µg/mm2, Balton), 
Coroflex Please (1 µg/mm2, B. Braun), Taxus (1 µg/ 
/mm2, Eurocor) and Apollo (1 µg/mm2, IK), whereas 
olimus-eluting stents (OES) were as follows: evero-
limus-eluting stents (Xience, Abbott Vasc; Promus, 
Boston Scientific), sirolimus-eluting stents (Cypher, 
Cordis; Prolim, Balton; Orsiro, Biotronik; Cre8, CiD), 
biolimus-eluting stents (Biomime, Biomime; Bio-
matrix, Biosensors) and zotarolimus-eluting stents 
(Resolute Integrity, Medtronic).
Follow-up
Clinical follow-up was performed with office 
visits or by telephone at 1 and 12 months after 
intervention. Adverse events were monitored 
throughout the study period. Follow-up coronary 
angiography was performed at 12 months unless 
clinically indicated in advance.
Endpoints
The primary endpoint was the cumulative rate 
of major adverse cardiovascular events (MACE) 
consisting of cardiac death, myocardial infarction 
(MI) and target lesion revascularization (TLR). Sec-
ondary endpoints included cardiac death, all-cause 
death, MI, TLR, target vessel revascularization 
(TVR), stent thrombosis, and device success [8]. 
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Statistical analysis
Continuous variables were presented as mean 
± standard deviation (SD). Categorical data were 
presented as numbers (%). Continuous variables 
were compared using an unpaired Student two-
-sided t test, and categorical data using the c2 test 
or Fisher exact test, as appropriate. If distribution 
was not normal (verified with the Shapiro-Wilk 
test), Wilcoxon signed-rank tests and Mann-Whit-
ney U-tests were used. P values of < 0.05 were 
considered statistically significant. In further analy-
sis univariate and multivariate logistic regression 
analyses were performed. The multivariate analy-
sis was performed with AIC minimization method. 
Statistical analyses were performed using R 3.0.2 
for OS (R Foundation, Vienna, Austria).
Results
Four hundred and forty five (445) patients, 
with 222 patients in BiOSS group and 223 patients 
in rDES group, were analyzed. Mean age was 
66.4 ± 9.5 years. Baseline characteristics of the 
whole population is presented in Table 1. There 
were no significant differences between subgroups 
in the whole population, apart from the diabetes 
rate which was higher in the BiOSS group (40.5% 
vs. 28.3%, p = 0.007). In 26.7% cases the proce-
dures were performed within distal LM, and true 
bifurcations accounted for 81.6% treated lesions. 
Procedural aspects are displayed in Table 2. There 
were 30.5% of PES within rDES group, while in 
the BiOSS group — 54%. There was a significantly 
higher rate of MV predilatation (71.3% vs. 61.7%, 
p = 0.035), FKB (49.3% vs. 32%, p < 0.001) and 
proximal optimization technique (POT) (68.6% vs. 
37.4%, p < 0.001) in the rDES group compared 
with the BiOSS group. 
At 12 months, within the whole population, no 
statistical differences in terms of MACE, TLR, MI 
or cardiac death between rDES and BiOSS groups 
were observed (Fig. 1). More detailed analysis con-
sidering type of drug eluting from the stent (Table 3) 
showed a trend for a higher rate of MACE in PES 
subgroup compared with OES subgroup (19.1% 
vs. 10.9%, p = NS) in rDES group whereas in Bi-
OSS group the difference between paclitaxel and 
sirolimus version was smaller (13.3% vs. 11.8%, 
p = NS). Interestingly, the same analysis for TLR 
rate showed the highest value in PES group, while 
the smallest in -olimus group (14.7% vs. 5.2%, 
p = NS). In the BiOSS group TLR rate did not 
Table 1. Baseline whole population clinical characteristics.
Parameter Total
N = 445
BiOSS group
N = 222
rDES group
N = 223
P
Age [years] 66.4 ± 9.5 66.5 ± 9.8 66.4 ± 9.20 0.698
Women 126 (28.3%) 62 (27.9%) 64 (28.7%) 0.916
Hypertension 351 (78.9%) 180 (81.1%) 171 (76.7%) 0.296
Hypercholesterolemia 310 (69.7%) 160 (72.1%) 150 (67.3%) 0.303
Diabetes type 2 153 (34.4%) 90 (40.5%) 63 (28.3%) 0.007
Diabetes type 2 on insulin 39 (8.8%) 23 (10.4%) 16 (7.2%) 0.246
Prior myocardial infarction 189 (42.5%) 99 (44.6%) 90 (40.4%) 0.389
Prior PCI 227 (51%) 112 (50.5%) 115 (51.6%) 0.85
Coronary artery bypass graft 43 (9.7%) 21 (9.5%) 22 (9.9%) 0.99
Chronic kidney disease 42 (9.4%) 23 (10.4%) 19 (8.5%) 0.521
History of smoking 104 (23.4%) 47 (21.2%) 57 (25.6%) 0.314
Clinical indication for PCI:
Planned PCI 372 (83.6%) 186 (83.8%) 186 (83.4%) 0.99
UA/NSTEMI 73 (16.4%) 36 (16.2%) 37 (16.6%) 0.99
True bifurcation 363 (81.6%) 178 (80.2%) 185 (83%) 0.466
False bifurcation 82 (18.4%) 44 (19.8%) 38 (17%)
Left main bifurcation 119 (26.7%) 62 (27.9%) 57 (25.6%) 0.594
Non-left main bifurcation 326 (73.3%) 160 (72.1%) 166 (74.4%)
Data are shown as mean ± standard deviation or number (percentage). PCI — percutaneous coronary intervention; UA/NSTEMI — unstable 
angina/non-ST-elevation myocardial infarction; rDES — regular drug eluting stents; BiOSS — Bifurcation Optimization Stent System Clinical 
Program
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differ significantly between paclitaxel and -olimus 
versions (11.7% vs. 9.8%, respectively). 
When taking into consideration diabetes melli-
tus (DM), there was no difference in BiOSS group in 
terms of MACE in DM and non-DM groups (12.2% 
vs. 12.9%, p = NS), whereas in rDES group pres-
ence of DM mattered (20.6% vs. 10.6%, p = 0.02, 
respectively DM vs. non-DM groups) (Table 4). 
The same analysis showed a maintenance of such 
a relation for TLR rate. This parameter was sig-
nificantly higher for DM population treated with 
rDES (14.3% vs. 5.6%, p = 0.03) and did not dif-
Figure 1. Kaplan-Meier curves for major adverse cardiovascular events in the whole population.
Table 2. Procedural whole population characteristics.
Parameter Total BiOSS group rDES group P
Main vessel predilatation 296 (66.5%) 137 (61.7%) 159 (71.3%) 0.035
Side branch predilatation 139 (31.2%) 74 (33.3%) 65 (29.1%) 0.358
Nominal predilatation balloon diameter [mm] – 2.5 ± 0.5 2.4 ± 0.3 0.21
Nominal predilatation balloon length [mm] – 13 ± 2.1 14 ± 2.9 0.19
Predilatation pressure [atm] – 14 ± 2.1 15 ± 2.8 0.67
Nominal postdilatation balloon diameter [mm] – 3.8 ± 0.5 3.5 ± 0.4 0.11
Nominal postdilatation balloon length [mm] – 8 ± 3.1 12 ± 3.4 0.07
Postdilatation pressure [atm] – 18 ± 3.4 19 ± 3.1 0.17
Nominal stent diameter [mm] – – 3.3 ± 0.5
Nominal stent diameter in main vessel [mm] – 3.7 ± 0.4 –
Nominal stent diameter in main branch [mm] –  3.0 ± 0.4 –
Nominal stent length [mm] – 17.6 ± 2.6 20.3 ± 6.6 0.08
Drug-eluting stent type:
-olimus eluting – – 155 (69.5%)
paclitaxel eluting – – 68 (30.5%)
Proximal optimization technique 236 (53%) 83 (37.4%) 153 (68.6%) < 0.001
Final kissing balloon 181 (40.7%) 71 (32%) 110 (49.3%) < 0.001
Additional stent in side branch 37 (8.3%) 22 (9.9%) 15 (6.7%) 0.235 
Data are shown as mean ± standard deviation or number (percentage). rDES — regular drug eluting stents; BiOSS — Bifurcation Optimization 
Stent System Clinical Program
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fer significantly within the BiOSS group (8.9% vs. 
12.1%, respectively DM vs. non-DM). 
Also, the analysis considering division into LM 
and non-LM bifurcation location in treated patient 
showed very interesting data (Table 5). First of all 
MACE rate was the smallest in LM patients treated 
with BiOSS stent (8.1% vs. 15.8%, respectively 
BiOSS vs. rDES group) and moreover this value 
was lower than in non-LM group (14.4% vs. 12.7%, 
respectively BiOSS vs. rDES group). 
Further, in order to determine prognostic 
factors for coronary bifurcation treatment with 
dedicated bifurcation stent BiOSS® and rDES 
univariate and multivariate regression analyses 
were performed. In multivariate analysis the odds 
for MACE (Table 6) decreased with female sex 
and with POT use, whereas the odds for MACE 
increased with DM treated with insulin and with 
MV predilatation. When performing regression 
analyses separately in BiOSS and rDES subgroups, 
no significant differences from a mechanistic point 
of view were observed. In both subgroups POT 
played a key role (data not shown).
Additionally, in multivariate analysis, it was 
found that the odds for MACE in DM population 
decreased for BiOSS® stent implantation (OR 
Table 3. Twelve-month clinical results depending of the stent type used (whole population).
Parameter Total 
N = 445
BiOSS Expert 
N = 120
BiOSS LIM 
N = 102
DES limus 
N = 155
DES PES 
N = 68
P
MACE 58 (13%) 16 (13.3%) 12 (11.8%) 17 (10.9%) 13 (19.1%)* 0.277
Death 9 (2%) 2 (1.7%) 1 (1.0%) 4 (2.6%) 2 (2.9%) 0.78
MI 11 (2.5%) 2 (1.7%) 2 (2.0%) 5 (3.2%) 2 (2.9%) 0.84
TLR 42 (9.4%) 14 (11.7%) 10 (9.8%) 8 (5.2%) 10 (14.7%)* 0.08
*DES limus vs. DES PES; DES — drug eluting stent; MACE — major adverse cardiovascular event; MI — myocardial infarction; PES — pacli-
taxel eluting stent; TLR — target lesion revascularization
Table 4. Clinical results — DM vs. non-DM population.
DM Non-DM
Total
153 (34.4%)
DES
N = 63
BiOSS
N = 90
Total
292 (65.6%)
DES
N = 160
BiOSS
N = 132
MACE 24 (15.7%) 13 (20.6%) 11 (12.2%)0.067 34 (11.6%) 17 (10.6%)* 17 (12.9%)
MI 4 (2.6%) 1 (1.6%) 3 (3.3%) 7 (2.4%) 6 (3.8%) 1 (0.8%)
Death 4 (2.6%) 3 (4.8%) 1 (1.1%) 5 (1.7%) 3 (1.9%) 2 (1.5%)
TLR 17 (11.1%) 9 (14.3%) 8 (8.9%)0.309 25 (8.6%) 9 (5.6%)* 16 (12.1%)0.059
Total DM vs total non-DM = NS; *DES DM vs. DES non-DM; #BiOSS DM vs. BiOSS non-DM = NS; DES — drug eluting stent; DM — diabetes 
mellitus; MACE — major adverse cardiovascular event; MI — myocardial infarction; TLR — target lesion revascularization
Table 5. Clinical results — LM vs. non-LM population.
LM Non-LM
Total
119 (26.7%)
DES
N = 57
BiOSS
N = 62
Total
326 (73.3%)
DES
N = 166
BiOSS
N = 160
MACE 14 (11.8%) 9 (15.8%) 5 (8.1%) 44 (13.5%) 21 (12.7%) 23 (14.4%)
MI 2 (1.7%) 2 (3.5%) 0 (0%) 9 (2.8%) 5 (3%) 4 (2.5%)
Death 2 (1.7%) 2 (3.5%) 0 (0%) 7 (2.1%) 4 (2.4%) 3 (1.9%)
TLR 11 (9.2%) 6 (10.5%) 5 (8.1%) 31 (9.5%) 12 (7.2%) 19 (11.9%)0.187
Total LM vs. total non-LM = NS; DES — drug eluting stent; LM — left main; MACE — major adverse cardiovascular event; MI — myocardial 
infarction; TLR — target lesion revascularization
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0.175, 95% CI 0.045–0.609), p = 0.008 and OR 
0.178, 95% CI 0.048–0.598, respectively) and with 
POT use (OR 0.043, 95% CI 0.006–0.197 and OR 
0.057, 95% CI 0.011–0.222, respectively).
The multivariate analysis considering LM lo-
cation showed that the odds for MACE significantly 
decreased with age (OR 0.908, 95% CI 0.838–0.976, 
p=0.012), whereas it significantly increased in 
diabetes treated with insulin (OR 20.391, 95% CI 
1.535–297.915, p = 0.021), smoking (OR 5.921, 
95% CI 1.566–25.650, p=0.011) and MV predilata-
tion (OR 11.557, 95% CI 1.925–222.486, p = 0.027).
Discussion
The main findings of this study are: 1) There 
was no statistically significant difference between 
total BiOSS group and total rDES group regard-
ing combined primary endpoint (MACE) as well 
as with regards to secondary endpoints (death, 
cardiac death, MI or TLR), however numerically 
the worst results were observed in paclitaxel-
-eluting rDES subgroup, whereas there was no 
difference between BiOSS Expert, BIOSS LIM 
and -olimus-eluting rDES, 2) Sub-analysis regard-
ing the type of the antiproliferative drug revealed 
that in terms of TLR rate, the best results were 
found in -olimus-eluting rDES subgroup while 
the worst in paclitaxel-eluting rDES subgroup, 
on the contrary there was no difference between 
BiOSS Expert, BIOSS LIM, 3) There was a very 
strong trend in favor of BiOSS stents compared to 
rDES stents in terms of MACE rate in the diabetic 
subpopulation, additionally results for total BiOSS 
group did not differ significantly between diabetic 
and non-diabetic subpopulations, 4) The analysis 
taking into consideration bifurcation location 
showed that there was a trend for better results 
in terms of MACE and TLR rates in the case of 
LM subgroup when the BiOSS stent was used, 
Table 6. Logistic regression for major adverse cardiovascular events in the whole population.
Variate Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Group: BiOSS vs. DES 0.918 (0.507–1.657) 0.777
Group: BiOSS Expert vs. DES 1.001 (0.490–1.971) 0.998
Group: BiOSS LIM vs. DES 0.824 (0.365–1.730) 0.621
Sex: female vs. male 0.447 (0.190–0.933) 0.045 0.433 (0.178–0.942) 0.047
Age [increase per 1 year] 0.994 (0.964–1.026) 0.708
NSTEMI/UA 2.490 (1.250–4.776) 0.007 1.901 (0.913–3.810) 0.076
Arterial hypertension 1.461 (0.695–3.462) 0.349
Diabetes 1.194 (0.641–2.175) 0.568
Diabetes on insulin 2.671 (1.129–5.826) 0.018 2.779 (1.100–6.593) 0.024
Dyslipidemia 1.018 (0.545–1.985) 0.956
Prior myocardial infarction 1.287 (0.710–2.324) 0.402
Prior PCI 0.873 (0.482–1.575) 0.651
Coronary artery bypass graft 1.623 (0.631–3.679) 0.275
Chronic kidney disease 0.817 (0.237–2.152) 0.712
Smoking 1.318 (0.661–2.502) 0.413
Ture bifurcation 2.179 (0.914–6.450) 0.111
Left main bifurcation 0.931 (0.493–1.848) 0.831
Main vessel predilatation 2.501 (1.233–5.628) 0.017 2.191 (1.042–5.066) 0.049
Side branch predilatation 1.405 (0.752–2.565) 0.275
Side branch stenting 1.260 (0.415–3.142) 0.648
Final kissing balloon 0.801 (0.427–1.460) 0.476
Proximal optimization technique 0.241 (0.118–0.462) 0.000 0.208 (0.097–0.419) 0.000
Acute lumen gain 0.675 (0.426–1.144) 0.253 0.875 (0.776–1.234) 0.453
Late lumen gain 1.763 (1.102–2.101 0.041 1.432 (0.987–1. 902 0.090
CI — confidence interval; PCI — percutaneous coronary intervention; OR — odds ratio; UA/NSTEMI — unstable angina/non-ST-elevation 
myocardial infarction
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5) In the regression analysis POT technique had 
the largest influence on lowering the MACE rate, 
whereas MV predilatation had the largest influence 
on increasing the MACE rate both in BiOSS as well 
as in the rDES groups.
The BiOSS® (Bifurcation Optimization Stent 
System) Clinical Program was started in 2008. The 
first BiOSS® stent was a bare metal one, but shortly 
after a paclitaxel-eluting version was introduced 
to the market — the BiOSS Expert® stent. After 
acceptable results of the BiOSS Expert® stent in 
the all-comer population [9] as well as in distal 
LM stenosis [10] a way for improvement was to 
change the paclitaxel into the -olimus drug. The 
sirolimus was chosen and the BiOSS LIM® stent 
was developed. Unfortunately, 1-year results for 
BiOSS® Expert and BIOSS® LIM were quite compa-
rable between Registries as well as for POLBOS I 
and POLBOS II trials. This could be explained by 
an initially lower concentration of sirolimus than 
is presently used (1.0 vs. 1.4 mg/mm2) [5, 6, 9, 11]. 
Also, the stent’s design reconstructed natural 
relations between all three parts of bifurcation 
and was to play an important role as well. The 
lack of differences between MACE rates in case 
of both BiOSS® stents and -olimus-eluting rDES 
with simultaneous differences regarding TLR 
in favor of -olimus-eluting rDES might suggest 
a protective effect of bigger neointimal proliferation 
reflected by higher late lumen loss in BiOSS stents 
caused by relatively big strut cross-sectional area 
> 0.01 mm2 [12]. 
In our analysis TLR and MACE rates for 
BiOSS and rDES were 10.8% vs. 8.1% and 12.6% 
vs. 13.5%, respectively. In the paper by Chen et al. 
[13], after 12-month follow-up results in paclitaxel 
(PES) group differed significantly with sirolimus 
(SES) group regarding to the rate of TLR, TVR and 
MACE, 12.2% vs. 3.2%, 14.4% vs. 4.9% and 20% 
vs. 10.3%, respectively. Also, in a meta-analysis it 
was proved that when comparing with PES, SES 
reduced the incidence of TLR, main-branch reste-
nosis and MACE in coronary bifurcation interven-
tion, while the risk of stent thrombosis was similar 
between SES and PES groups [14]. Presently, zo-
tarolimus (ZES) and everolimus (EES) are deemed 
to be the gold standard in drug-eluting stents [2, 
15]. Pan et al. [16] proved that EES and SES are 
equally effective in the treatment of coronary bifur-
cation lesions (1-year MACE rate of 6.1% and 6.2%, 
respectively), while Sgueglia et al. [17] disclosed 
that in the treatment of bifurcations SES is better 
than ZES and inferior to EES (target bifurcation 
failure rate: 7.9%, 18%, 3.3%, respectively). It is 
very likely that many additional parameters such 
as selection of patients, protocol of intervention or 
indications for additional stent implantation deter-
mine the results of these mainly one-center studies. 
In addition, it should be stressed that, contrary to 
a majority of other studies, there was a very high rate 
of control angiography (above 90%) in the present 
study there were significant increases in TLR ratio.
Interestingly, this study obtained numerically 
better results for BiOSS than in rDES subgroups in 
cases of patients with DM. Vascular response in pa-
tients with DM and dyslipidemia differ significantly 
when compared with healthy controls in terms of 
increased neointimal area, delayed reendotheliali-
zation, and greater, persistent vascular inflamma-
tion [18]. Nevertheless, data suggest that DM and 
non-DM lesions showed similar vessel response 
in both in-stent and reference segments, regard-
less of the DES type [19]. The follow-up lumen 
in DM patients seems to be determined primarily 
by the smaller lumen at postprocedure rather than 
exaggerated neointima within the stent or plaque 
proliferation at the reference segments. Here, we 
can see the role of BiOSS design offering bigger 
lumen increase and laminar flow. Also, neointimal 
hyperplasia persists at least up to 6 months after 
SES implantation, which may be partly related to 
an exaggerated inflammatory response within the 
blood vessel wall. It is suggested that direct ben-
eficial effects of anti-diabetic and anti-inflammation 
medications might decrease the risk of restenosis 
after stenting. One may presume that the BiOSS 
biodegradable polymer might also play such a role 
[20]. Nevertheless, one must admit that results 
obtained in rDES subgroups in POLBOS trials in 
diabetic patients were relatively high in comparison 
to other papers (POLBOS rDES MACE 20.6%, 
TLR 14.3%; Liu et al.: MACE 13.2%, TLR 7.9%, 
Meelu et al.: MACE 7.4%, TLR 3.7%) [21, 22]. 
A very high rate of control angiography in the 
present study could be one of the explanations. 
Both the results of POLBOS I and POLBOS II, 
as well as pooled data have shown that the BiOSS® 
stent acts well in distal LM stenosis [23]. There 
was no difference between sirolimus- and pacli-
taxel-eluting BiOSS® stents. This suggests that 
the BiOSS® construction itself played a key role. 
Regression analysis suggested that the higher MV/ 
/MB rate the lower the odds for MACE (MACE, OR 
0.87, p = 0.057). This finding supports the above 
mentioned hypothesis. MACE and TLR rates were 
higher when compared with the recent findings of 
EXCEL or NOBLE trials, but in other studies con-
trol angiography was mandatory and such a study 
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design increases values of the abovementioned 
endpoints [24, 25]. 
In the present analysis it was found that in 
regression analysis female sex and POT decreased 
the odds for MACE, whereas MV predilatation and 
DM treated with insulin increased the odds for 
MACE. These findings are similar to other studies. 
In the MITO Registry the independent predictors 
of main branch in-stent restenosis were calcifica-
tion (HR 2.284, p = 0.016), true-bifurcation (HR 
2.331, p = 0.024), insulin-dependent DM (insulin-
DM) (HR 2.259, p = 0.048). Furthermore, POT 
(HR 0.548, p = 0.077), full LM cover approach 
(HR 0.605, p = 0.093) and greater minimal lumen 
diameter (HR 0.611, p = 0.062) had a tendency 
to reduce main branch in-stent restenosis [26]. 
Whereas, Wihanda et al. [27] disclosed the follow-
ing factors associated with in-stent restenosis: 
stent-type (OR = 4.83, 95% CI 2.51–9.30), stent 
length (OR = 3.71, 95% CI 1.99–6.90), bifurcation 
lesions (OR = 2.43, 95% CI 1.16–5.10), smoking 
(OR = 2.30, 95% CI 1.33–3.99), vascular diameter 
(OR = 2.18, 95% CI 1.2–3.73), hypertension (OR 
= 2.16, 95% CI 1.16–4.04) and DM (OR = 2.14, 
95% CI 1.23–3.70).
Nevertheless, POT and MV predilatation is-
sues require separate analysis. Appropriate stent 
apposition in the proximal MV is achieved by POT, 
which is performed by dilating the proximal MV 
stent from the proximal stent edge to just proximal 
to the carina, using a short oversized balloon. POT 
improving stent apposition facilitates SB access 
(with scaffolding of its ostium), reduces risk of ac-
cidental abluminal rewiring, lowers the risk of stent 
distortion by catheter collision and as consequence 
enhances luminal postprocedural flow. Thus, POT 
should be considered as a standard step in bifurca-
tion treatment [28]. POT was performed two-fold 
more often in rDES group than in the BiOSS group 
due to belief in POT-like effect of BiOSS stents, 
and in the regression analysis it positively cor-
related with better clinical outcomes. This seems 
to attest to it, that results in BiOSS group might 
be improved by applying obligatory POT. POT in 
BiOSS might have been disclosed important since 
in cases  of thick strut stainless steel BiOSS plat-
form, semi-compliant delivery balloon Bottle might 
not be so efficient as real POT performed with 
a non-compliant balloon.
Limitations of the study
Although the sample size was relatively small 
(it is in line with similar studies found in the 
literature) it was based on predefined statistical 
considerations, and primarily affects the robust-
ness of observations of subgroup analyses. The 
use of multiple stent types and drugs in the control 
group is also a limitation, although this aspect of the 
design was intended to replicate real-world clinical 
practice. Finally, the differences in FKB and POT 
strategies between the study groups might have 
also influenced the results.
Conclusions
There was no statistically significant dif-
ference between total BiOSS group and total 
rDES group regarding combined primary endpoint 
(MACE) as well as regarding secondary endpoints 
(death, cardiac death, MI or TLR), however the 
worst results were observed in paclitaxel-eluting 
rDES subgroup, whereas there was no difference 
between BiOSS Expert, BIOSS LIM and -olimus- 
-eluting rDES. 
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